Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Disc Medicine Inc. is currently navigating 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are split among 3 distinct examiners, which indicates that each pending matter is under the review of a different patent office official. This distribution requires the applicant to manage three separate sets of examiner expectations and timelines.
The prosecution activity is also spread across 3 distinct art units, suggesting that the company's pharmaceutical developments fall into three different regulatory categories. DONOGHUE, BRITTNEY ERIN is the busiest examiner for this portfolio and is currently overseeing 1 busiest examiner pending office action. This examiner is responsible for 1 of the 3 pending office actions currently active.
Strategic management of the 3 pending office actions requires a focus on the individual requirements of the 3 distinct art units. Because there is no overlap among the 3 distinct examiners, the applicant cannot rely on a single prosecution strategy. Instead, the company must tailor its responses to the specific feedback of each examiner, including the 1 busiest examiner pending action assigned to DONOGHUE, BRITTNEY ERIN.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DONOGHUE, BRITTNEY ERIN | 1 | 58.7% | +47.4% |
| NOLAN, JASON MICHAEL | 1 | 66.6% | -27.2% |
| PATEL, SAGAR S | 1 | 75.7% | +34.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18673941 | ANTI-TMPRSS6 ANTIBODIES AND USES THEREOF | DONOGHUE, BRITTNEY ERIN | — |
| 18290403 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS | PATEL, SAGAR S | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| 1623 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18673941 | ANTI-TMPRSS6 ANTIBODIES AND USES THEREOF | DONOGHUE, BRITTNEY ERIN | 1675 | §103§112DP | Non-Final OA | — | Pending | May 24, 2024 |
| 18562510 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH A SOLID FORM OF BITOPERTIN | NOLAN, JASON MICHAEL | 1623 | §102§103§112DP | Non-Final OA | — | Pending | Nov 20, 2023 |
| 18290403 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS | PATEL, SAGAR S | 1626 | §103§112DPOther | Non-Final OA | — | Pending | Nov 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDisc Medicine Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Brittney Erin Donoghue has the most, with 1 of Disc Medicine Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
